Literature DB >> 3840906

Release and degradation of neurotensin during perfusion of rat small intestine with lipid.

C F Ferris, R E Carraway, R A Hammer, S E Leeman.   

Abstract

The levels of neurotensin (NT) and its metabolite, the N-terminal octapeptide (NT1-8), identified by HPLC and measured by RIA, were increased in the hepatic-portal circulation of the anesthetized rat during perfusion of the small intestine with a lipid solution, while levels of both peptides remained unchanged in the general circulation. There was no significant arteriovenous difference for NT or NT1-8 during saline perfusion of the small intestine. Plasma collected from the superior mesenteric vein during the infusion of [3H]NT into the superior mesenteric artery showed major peaks of radioactivity with the retention times of NT1-8 and NT1-11 on HPLC. Only 12% of the radioactivity recovered from plasma was intact NT. These studies demonstrate that chromatographically identified NT and its metabolite, NT1-8, are elevated in the portal circulation but not systemic circulation during lipid perfusion and that the small intestine may be both the site of release and metabolism of NT.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3840906     DOI: 10.1016/0167-0115(85)90191-0

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  11 in total

1.  Characterization of promoter elements regulating the expression of the human neurotensin/neuromedin N gene.

Authors:  Xiaofu Wang; Pat Gulhati; Jing Li; Paul R Dobner; Heidi Weiss; Courtney M Townsend; B Mark Evers
Journal:  J Biol Chem       Date:  2010-10-28       Impact factor: 5.157

2.  Curcumin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells.

Authors:  Xiaofu Wang; Qingding Wang; Kirk L Ives; B Mark Evers
Journal:  Clin Cancer Res       Date:  2006-09-15       Impact factor: 12.531

3.  Suppression of neurotensin receptor type 1 expression and function by histone deacetylase inhibitors in human colorectal cancers.

Authors:  Xiaofu Wang; Lindsey N Jackson; Sara M Johnson; Qingding Wang; B Mark Evers
Journal:  Mol Cancer Ther       Date:  2010-07-27       Impact factor: 6.261

4.  [Metabolic parameters and neurotensin liberation after resection of the small intestine, syngeneic and allogeneic segment transplantation the rat].

Authors:  R Schlemminger; S Lottermoser; H Sostmann; H Köhler; R Nustede; A Schafmayer
Journal:  Langenbecks Arch Chir       Date:  1993

5.  High plasma levels of pro-NT are associated with increased colon cancer risk.

Authors:  Li Li; Heidi L Weiss; Jing Li; Zhengyi Chen; Leslie Donato; B Mark Evers
Journal:  Endocr Relat Cancer       Date:  2020-11       Impact factor: 5.678

6.  Characterization of promoter elements required for cell-specific expression of the neurotensin/neuromedin N gene in a human endocrine cell line.

Authors:  B M Evers; X Wang; Z Zhou; C M Townsend; G P McNeil; P R Dobner
Journal:  Mol Cell Biol       Date:  1995-07       Impact factor: 4.272

Review 7.  A Review of the Role of Neurotensin and Its Receptors in Colorectal Cancer.

Authors:  Shengyang Qiu; Gianluca Pellino; Francesca Fiorentino; Shahnawaz Rasheed; Ara Darzi; Paris Tekkis; Christos Kontovounisios
Journal:  Gastroenterol Res Pract       Date:  2017-02-20       Impact factor: 2.260

Review 8.  Neurotensin pathway in digestive cancers and clinical applications: an overview.

Authors:  Niki Christou; Sabrina Blondy; Valentin David; Mireille Verdier; Fabrice Lalloué; Marie-Odile Jauberteau; Muriel Mathonnet; Aurélie Perraud
Journal:  Cell Death Dis       Date:  2020-12-02       Impact factor: 8.469

9.  Effect of gut transposition on the expression of the endocrine gene neurotensin.

Authors:  X M Wang; R P Thomas; B M Evers
Journal:  J Gastrointest Surg       Date:  1998 May-Jun       Impact factor: 3.267

10.  Fasting Neurotensin Levels in Pediatric Celiac Disease Compared with a Control Cohort.

Authors:  Donatella Iorfida; Monica Montuori; Chiara Maria Trovato; Claudio Tiberti; Andrea Sansone; Salvatore Cucchiara; Francesco Valitutti
Journal:  Gastroenterol Res Pract       Date:  2020-02-22       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.